Dr. Abel has had a distinguished career in endocrine and metabolism research. His pioneering work on glucose transport and mitochondrial metabolism in the heart guides his current research interests: molecular mechanisms responsible for cardiovascular complications of diabetes. His laboratory has provided important insights into the contribution of mitochondrial dysfunction and aberrant insulin signaling, to heart failure risk in diabetes. Recent work has focused on mitochondrial mechanisms that mediate inter-organ crosstalk that may influence the pathophysiology of insulin resistance and mitochondrial pathways linking metabolism with increased risk for atherothrombosis.

Dr. Abel’s research program has been continually funded by the National Institutes of Health since 1995, and by the American Heart Association, the American Diabetes Association, and the Juvenile Diabetes Research Foundation. Dr. Abel is the recipient of numerous awards for scholarship and mentorship. He is an elected member of the American Association of Physicians (AAP), the American Society for Clinical Investigation (ASCI), National Academy of Medicine (NAM), and the American Clinical and Climatological Association (ACCA). Dr. Abel is the President-elect of the Endocrine Society.

Dr Aitken is strongly involved in surgical education and is a member of the Board of Vascular Training and co-chair of the Concord Institute of Academic Surgery. She has been awarded a number of prestigious research grants, including the inaugural Royal Australian College of Surgeons Senior Lecturer Fellowship, Vascular Foundation Grant and the University of Sydney John Brooke Moore Award.

Her relaxation and enjoyment came from developing school gardens and cooking programs to encourage use of fresh fruit and vegetables. During this time, Polly partnered with Charles Sturt University and 20 other organisations to survey 300 NSW stores west of the Great Dividing Range to collect data on food access and availability.

Government funding changes saw Polly return to Moree and apply for a scholarship to complete training at the University of Technology Sydney (UTS) to become a Credentialled Diabetes Educator.   She completed her qualification while working with the local ACCHS, providing a diabetes clinic and running cooking programs in the schools for parents. In the past eight years, Polly has completed two pictorial cookbooks that make eating healthy food easy and inexpensive.

Polly accepted a position in 2019 with Diabetes Queensland.  Western QLD PHN and Diabetes Queensland have developed a fly-in fly-out diabetes service for the communities of Mt Isa, Cloncurry and Julia Creek. Polly finds her greatest reward as a Dietitian and Diabetes Educator comes from providing clients with the skills to self-manage their diabetes and reduce diabetes distress.

Adam has experience in transitioning medical professionals looking to transition from employment to setting up their business. Adam understands the challenges to starting up a business, so works closely with his clients to keep things simple and provide all of the support needed to allow his clients to do what they do best. As part of his engagements with clients, Adam will help identify the cash flow issues arising when setting up a business, ensure that clients remain compliant with their obligations and will be there every step of the way as their business grows.

This experience of his allows Adam and the team at LDB to have a broad range of knowledge across the various accounting and taxation issues faced in multiple industries including the medical industry. This experience puts LDB in a position to provide excellent advice and client support and service for all client industries.

Anna currently provides diabetes education and pharmacy services in Bathurst, including an Indigenous Chronic Disease Clinic within a multi-disciplinary team, and outreach services to surrounding communities from within their GP practices. She is passionate about empowering patients, and the local healthcare professionals who support them, through education – particularly around medication management of diabetes.

She demonstrated that the adverse effects of high blood glucose apply not only to diabetes, but to obesity and cardiovascular disease. By establishing international standards and testing services for industry and compiling reliable databases, she facilitated epidemiological, agricultural and industrial research application of the GI around the world. By writing books and launching a food labelling program, she translated new knowledge into actions that helped millions of individuals to adopt healthier diets. She was awarded a Clunies Ross Science and Technology Medal in 2003, and in 2011 she was appointed a member of the Order of Australia. She is the proud recipient of two Nucleus cochlear implants.

The clinic was accredited as Diabetes Health Promotion Agency by the National Institutes of Health, Taiwan in 2012, and received double excellence award for diabetes care quality every year since 2012 to 2018

Present:

• Superintendent of Samuel Chen Clinic
• Executive Director, Taiwan Association of Clinical Diabetes
• President of Nantou County Clinic Association
• Deputy Secretary General, Taiwan Family Medicine Association
• Chief Executive Officer, Taiwan Medical Clinics Association

Returned to Adelaide in July 2003 as Renal Transplant Nephrologist. He is past Honorary Secretary Transplantation Society of Australia and New Zealand. He was appointed as the sole Australian Associate Editor for the International Society of Nephrology’s Journal Kidney International (2012-2017). He was the recipient of South Australian Tall Poppy Science Award for his research from the Government of South Australia in 2004. His total research funding since 1st July 2003 is over $10.2 million, including 2 CIA project grants from the NHMRC and Project grant funding from the JDRF for Clinical Islet Transplantation. In June 2016 he received JDRF USA funding for development of alternative sites for islet transplantation and was appointed to the International JDRF Islet Encapsulation Consortium. He is currently the Director of South Australia’s first (and only) Nationally Funded Centre for Islet Transplantation and the Head of Kidney and Pancreas Islet Transplantation at the Royal Adelaide Hospital. In 2013 he was the lead clinical investigator in the $59 million Collaborative Research Centre for Cell Therapy Manufacturing (CRC-CTM) to manufacture new technologies to support islet transplantation (2013-2018). He was awarded the Ian McKenzie Prize for Outstanding Contribution to Transplantation in 2013, from the Transplantation Society of Australia and New Zealand. He has 110 peer-reviewed publications and has supervised 16 Honours and PhD students to completion within the University of Adelaide. He is a consultant to the National Transplant Service and a member of the Renal Transplant Advisory Committee of the Transplantation Society of Australia and New Zealand.

He is married with 2 children, restores classic / vintage cars and collects antiquarian books.

A major research interest is studying how the modern diet leads to the initiation or worsening of inflammation and chronic disease, with a focus on diabetes and its complications. A/Prof Coughlan has already made a number of exciting and important observations in the preclinical space with respect to drug target identification and has now extended her research to translational studies. She currently holds funding from NHMRC and a Career Development Fellowship from the JDRF’s Australian Type 1 Diabetes Clinical Research Network for her work into diabetes and its complications.

He is also a Busselton Health Study investigator and an associate investigator on the United Kingdom Prospective Diabetes Study. He founded a tropical/infectious diseases research group that is involved in collaborative studies of malaria and bacterial infections in children and pregnant women in Papua New Guinea and other tropical countries. Professor Davis is author or co-author of more than 430 original research papers, the majority on diabetes, endocrinology, malaria and other tropical diseases. Professor Davis is a member and past Vice President of the Australian Diabetes Society, and was the Society’s 2014 Kellion Lecturer in recognition of his outstanding contribution to diabetes research and clinical care in Australia. He was recently a member of the Australian Government’s Commonwealth Science Council, and is currently Co-Deputy Chair of the Australian Government Medical Services Advisory Committee.

I completed the Diabetes Education qualification at Mayfield Education Centre, and have since worked in Aboriginal and Torres Strait Islander communities of Cape York as a Credentailled Diabetes Educator, having previously worked in the Western Desert, Arnhemland, Kimberley and Queensland in Midwifery and Primary Health care.

For the past 8 years I have  worked for Apunipima Cape York Health Council as a  CDE providing Diabetes  support management and prevention education to the people of  Cape  York , where I work  closely  with the Integrated  Team.

He received a PhD in immunology from the Weizmann Institute of Science, followed by a postdoctoral fellowship at Yale University School of Medicine. Dr. Elinav has published more than 140 publications in leading peer-reviewed journals, including major recent discoveries related to the effects of host genetics, innate immune function and environmental factors, such as dietary composition and timing, on the intestinal microbiome and its propensity to drive multi-factorial disease. His honors include multiple awards for academic excellence including the Claire and Emmanuel G. Rosenblatt award from the American Physicians for Medicine (2011), the Alon Foundation award (2012), the Rappaport prize for biomedical research (2015) the Levinson award for basic science research (2016), and is an elected member, European Molecular Biology Organization (EMBO). Since 2016 he is a senior fellow at the Canadian Institute For Advanced Research (CIFAR), and since 2017 he’s an international scholar at the Howard Hughes Medical Institute (HHMI)  and the Bill & Melinda Gates Foundation.

She is also the Director of Diabetes at Austin Health, where she co-ordinates the clinical care of inpatients and outpatients with diabetes. She heads diabetes and obesity clinical trials at CREDO-Centre for Centre for Research and Education in Diabetes and Obesity and has over 100 publications and has obtained a total of over $4.5 million of research funding.

His clinical work and his main research activities are dedicated to the largely unknown interactions of the exocrine and the endocrine pancreas, especially focussing on pancreatogenic diabetes.

He is a popular speaker at national and international conferences within his area of expertise. His research group has proposed the classification criteria for pancreatogenic diabetes and he very recently contributed the European Guidelines on Chronic Pancreatitis heading the diabetes section.

Besides that, he regularly serves as a reviewer for NIH and many renowned journals.

She is committed to improving the care for heart attack patients- using her knowledge of molecular and cellular biology to develop methods of identifying those at highest risk of adverse outcome, and discovering novel therapies to prevent and treat events, inspired by her clinical work as an interventional cardiologist. She has dedicated herself throughout her career to unravelling key mechanisms underlying susceptibility and response to heart attack, with studies extending from the bench to large cohort studies and clinical trials. Discoveries in her Laboratory have been published in leading journals Circulation, JACC and European Heart Journal, with > 140 publications. GF is a principal investigator on grants >$8 mill. Having recently completed a co-funded NHMRC CDF and Heart Foundation Future Leader Fellowship, she was awarded a National Health and Medical Research Council (NHMRC) Excellence Award for Top Ranked Practitioner Fellow (Australia), commencing in 2018. She is committed to the advancement of her field and serves as a member of the Editorial Board of leading international cardiovascular journals Circulation and Cardiovascular Research, as well as being a founding editorial board member for Redox Biology, and an Associate Editor for Heart, Lung and Circulation. Her research and clinical perspective and leadership are recognised by her membership of the Scientific Board of Cardiac Society of Australia and New Zealand (responsible for International Relations), and her appointment to the Expert Advisory Panel for NHMRC Structural Review of Grants Program (2016-17), and as well as the Clinical Committee of the Heart Foundation. She is committed to the promotion and advocacy of cardiovascular research, working as President of the Australian Cardiovascular Alliance with a national team to secure $220 Million Federal funding for the Mission for Cardiovascular Health, as well as a member of the NSW CVD Advisory Committee. She is a graduate of the Australian Institute of Company Directors and serves/has served as a non-executive Director on multiple community Boards.

Dr. Gerstein’s research has been published in over 400 papers, spans 50 countries, and has been funded by the NIH, the Canadian Institutes of Health Research, the Heart and Stroke Foundation of Canada, the Canadian Diabetes Association and the pharmaceutical industry. His research focuses on: a) the prevention and therapy of diabetes and its many consequences; b) the relationship between dysglycemia (a term he coined in 1995), cardiovascular outcomes, cognitive impairment, other diabetes-related chronic consequences, and new diabetes; c) strategies for type 2 diabetes remission; d) novel biomarkers for cardiovascular disease in diabetes; and e) the biologic basis of glucose-related health consequences. In 2016 he produced and distributed a music video to mitigate the impact of diabetes on affected people and their families. In 2012 he received the Canadian Diabetes Association’s Lifetime Achievement Award.

Currently a Senior Research Fellow at the University of Queensland Diamantina Institute, her laboratory now focuses on the role of the gut microbiota in type 1 diabetes as well as immunotherapeutic approaches aimed at restoring immune tolerance in type 1 diabetes. Recently, she demonstrated a role for genetic control of immune development in shaping the gut environment and the microbiota in type 1 diabetes. Her current research uses state-of-the-art proteomic techniques to probe how disturbances in the gut microbiota in children with type 1 diabetes and at-risk family members impact host intestinal and pancreatic function. She is currently involved in a clinical trial of a microbiome-targeting dietary supplement aimed at restoring a healthy microbiome and immune tolerance with an ultimate aim of preventing type 1 diabetes.

His research spans insulin receptor structure-function, pre-clinical diagnosis and trials to prevent type 1 diabetes, proinsulin as a primary autoantigen in type 1 diabetes, rotavirus as an environmental trigger in type 1 diabetes, CD52 as an immune regulator and therapeutic, and the microbiome and other ‘omes in development of T1D – in over 550 scientific papers.  He has been Secretary and President of the Australian Diabetes Society, and the Immunology of Diabetes Society, and the recipient of awards including the C.J. Martin Fellowship, Wellcome Medal, Susman Prize, Kellion Medal, Rumbough Research Prize and several Lifetime Achievement Awards.

Kristine is particularly interested in supporting the psychological wellbeing of all her patients and how to best meet the needs of a large cohort of culturally and linguistically diverse patients.

Kristine’s particular research interests include automated insulin therapy, continuous glucose monitoring and preconception education for adolescent girls with diabetes.

During this time she began travelling with the diabetes outreach team to remote Indigenous Communities in Cape York, and for the past 12 has been working exclusively in this area. She works as part of a broader multidisciplinary team, visiting regular communities each week, spreading the self-management message and advocating for her clients at every opportunity. She believes strongly that all people with diabetes should have access to the same resources (whether medical, technological or educational) and that the provision of culturally appropriate diabetes education by CDEs in remote communities can have a significant impact on long term outcomes. She was the recipient of the Jan Baldwin CDE of the Year for 2017.

Whether these tools improve glycaemic health in humans, and be sustainable, is unclear. She also seeks to understand the mechanisms underpinning improvements in glucose control in humans. Leonie has published more than 100 research articles in nutrition, metabolism and obesity. She is Vice President of the Australia New Zealand Obesity Society, Associate Editor for Obesity, and Obesity Research and Clinical Practice and Editor of the Clinical Trials Corner for Nutrition and Healthy Aging.

His work has spanned a number of aspects of the pathogenesis of autoimmune diabetes including the immune mechanisms and the effects of autoimmunity on beta cells, with studies in preclinical and with clinical samples. A large portion of his studies involve understanding how immune therapies modify pathogenic immune responses. His lab identified a subpopulation of beta cells that appear to resist immune attack. He developed an assay to measure β cell death in vivo and described changes in beta cells that occur in response to immunologic stressors which, he postulated may enable their survival. His laboratory has a long standing interest in developing tools to analyze autoantigen specific T cells in patients with Type 1 diabetes and has used Class I MHC tetramers to analyze these cells in clinical trials and more recently developed T cell libraries for this purpose. His group was the first to identify autoimmune diabetes induced with checkpoint inhibitors which has provided insights into the mechanisms of Type 1 diabetes. He is a member of the Immune Tolerance Network Steering committee and the PI of the Yale Trial Net Center. He serves as Deputy Director for Translational Medicine in the Yale CTSA, and the Director of the Autoimmunity program in the Human Translational Immunology section of the Department of Immunobiology.

She leads a clinical, biochemical and molecular biomarker laboratory and has key roles in diabetes trials and studies including: REMOVAL, FAME-1, FIELD, T4DM, Hybrid Closed Loop trials, the DCCT-EDIC study, a CRE in Diabetic Retinopathy, an Australia China grant and a Program Grant. Alicia holds a NHMRC Practitioner Fellowship and is an Australian Cardiovascular Alliance Flagship Director (Precision Medicine). She has over 375 publications and 15 completed higher research degree candidates. She served 8-years on the ADS Council and is currently on the IDF-Western Pacific Region Executive Council, and President of the diabetes aid organisation Insulin For Life.

She has built a strong international reputation in community pharmacy health services research evidenced through grants, publications, and invitations to contribute to subject reviews. In 2016 she was awarded the prestigious Australasian Pharmaceutical Science Association (APSA) Medal which is APSA’s highest award and recognises an individual who has made a significant and lasting contribution to the pharmaceutical sciences and pharmacy practice.

Pete’s research interests are in the epidemiology and treatment of foot disease (ulcers, infections, ischaemia). He has an emerging international research track record in this field with >60 papers published and >$3.5 million in grant funding. And he currently holds an Early Career Fellowship with the Australia National Health and Medical Research Council.

Pete serves on many international diabetic foot disease committees and is the founding co-chair of Diabetic Foot Australia and secretary of the International Working Group of the Diabetic Foot Pressure Offloading Guideline Working Group.

Highlights included serving as the founding Chief Executive Officer of the National Indigenous Media Association of Australia, the peak body for Aboriginal and Torres Strait Islander media and communications and being the inaugural lecturer in broadcasting and communications at the Batchelor Institute for Indigenous Education.

More recently Chris has worked as an Indigenous Advisor to the Queensland Government and in senior engagement roles with several organisations including the University of Southern Queensland, the QLD Crime and Corruption Commission and providing culturally safe trauma informed assistance to First Nation survivors of institutional childhood abuse. He has deep connections to remote, regional and metro First Nation’s communities across Australia and an intimate understanding of cultural protocols, communications and engagement practises.

When Chris was diagnosed with type 2 diabetes in 2014 he embarked on a journey of learning and understanding around the condition which he brings to his role with Diabetes Australia and the National Diabetes Services Scheme.  Chris works closely with State and Territory diabetes organisations, ADS and ADEA, , Aboriginal and Torres Strait Islander peak bodies and community organisations to reduce the impact of diabetes in First Nations people. Chris brings enormous enthusiasm and community understanding to his role.

Kristine brings a wealth of experience to her role, having worked in clinical paediatrics, child development, early childhood nutrition in migrant and at-risk communities and child obesity prevention.  She is particularly interested in exploring diabetes and nutrition education and how it can best meet the needs of culturally and linguistically diverse families.

Her areas of research interest include responsive feeding in children aged under 5 years with T1D and optimizing engagement and service delivery for adolescents with T2D.

He has a secondary appointment in the Department of Human Genetics, where he is also Vice Chairman. He has served on advisory panels for the National Institutes of Health, the American Heart Association, and various private companies and organizations. Presently, he serves on the Board of Scientific Counselors, NHLBI. Among his awards are the Bristol-Myers Squibb Award for Distinguished Achievement in Research, the American Heart Association Duff Award, and the NAVBO Benditt Award.

As a part of this broader area, she also works on the other large datasets such as the National Diabetes Service Scheme (NDSS) linked to administrative data. Work on the NDSS has led to international status attested by invitations to the Diabetes and Cancer consortium, editor roles at Diabetes Research and Clinical practice and Atherosclerosis, and the presidency of the International Diabetes Epidemiology Group.

Professor Magliano has well developed epidemiological and biostatistical skills. Fifteen years of teaching of epidemiology for Monash University has meant that her conceptual skills in epidemiology are well developed and current. Furthermore, as the senior epidemiologist of the Australian Diabetes, Obesity and Lifestyle Study (AusDiab) for over 11 years, she has acquired real life epidemiological training by working directly in the field, conducting epidemiological analyses. In 2017 she was awarded a NHMRC Senior research fellowship and the Australian Jeff flack data award from the Australian Diabetes Council.

Together with colleagues at St. Vincent’s Institute of Medical research he pioneered the isolation of viable T cells from the residual pancreatic islets of organ donors who had T1D. Currently the group’s focus is on identifying antigens ‘seen’ by human islet-infiltrating T cells and developing murine models to investigate their pathogenicity. Eventually this work will contribute to the development of antigen-specific therapies to prevent, or cure, T1D.

Louise established and leads the Diabetes across the Lifecourse: Northern Australian Partnership. The partnership includes several large NHMRC-funded projects, including the Northern Territory and Far North Queensland Diabetes in Pregnancy Partnership and The PANDORA (Pregnancy And Neonatal Diabetes Outcomes in Remote Australia) Cohort Study. After completing the majority of her physician and endocrinology training at St Vincents Hospital Sydney, Louise moved to Darwin in 2002 to pursue her passion for improving the health of Indigenous Australians. Louise is currently on the Australian Diabetes Society Council and was previously a member of the Council of the Australasian Diabetes in Pregnancy Society. Louise has been providing clinical diabetes services to urban and remote NT communities for over 17 years, including more recently via telehealth.

She has been awarded a JDRF Early Career Fellowship in 2013; the prestigious Type 1 Millennium Award from Diabetes Australia – the largest allocated funding in Victoria in 2014 and awarded with the Career Development Award from JDRF in 2016. Dr. Mariño’s research focuses on investigating innovative dietary technologies that boost the good gut microbiota and modulate the immune system to tackle type 1 diabetes as shown in her latest work published in the prestigious scientific journal Nature Immunology (Mariño et. al., Nature Immunology, 2017) and she is the leader of a clinical trial that is underway.

The last 8 years in Paediatric Diabetes and Endocrine at the John Hunter Children’s Hospital. In clinical practice she regularly provide psychosocial assessment and interventions which includes financial support, behavioural management support, group work, advocacy, parental support, adolescent development guidance, therapeutic counselling regarding new diagnosis, grief, adjustment, trauma and mental health support. Her primary areas of interest remain on the safety and well being of vulnerable populations including children and families with high psychosocial risks.

Her work has identified that kidney development can be impaired during pregnancy by maternal stress, alcohol consumption or a poorly functioning placenta. Currently she is examining how this impacts on childhood growth and development risk for outcomes such as diabetes, high blood pressure, kidney dysfunction and obesity.

His main research interests are the identification of determinants or predictors (starting from very early life stages) of obesity and obesity related cardio-metabolic complications and the design, implementation and evaluation of the effectiveness of personalised nutrition and lifestyle optimization intervention programs, which aim to tackle obesity and related co-morbidities (i.e. type 2 diabetes, cardiovascular disease etc.) in children and adults.

Up to date, George has authored 164 research articles published in international peer-reviewed scientific journals with 4,145 citations and has an h-index of 30 (Scopus).

Kylie has both led and been involved in research projects that had the ultimate goal of supporting people to effectively manage and cope with chronic health conditions, such as obesity, diabetes, cancer and eating disorders. Kylie has a particular interest in what motivates people to make and sustain changes to health behaviours (such as physical activity and diet) and the social impact of living with a chronic health condition. Kylie is committed to conducting research that has an impact on practice and disseminating her research findings to healthcare professionals and consumers.

She has a PhD in Biochemistry and has worked in diabetes research at both the basic and clinical research level in both Australia and Europe.  She has always had an interest in glucose metabolism and its role in diabetes. She is keen to translate the results from the PREView Study to the clinical setting through rapid weight loss using a total diet replacement, and by promoting healthy diet and exercise habits, sustained by a behaviour change techniques in overweight and overweight patients with blood glucose levels in the range for pre-diabetes.

He is the current Chair of Chinese Society for Clinical Endocrinologists, president of Chinese Endocrine Society (2008-2012), Chief Editor of the Journal of Chinese Endocrinology and Journal of Diabetes. He is “Changjiang” Professor, chief scientist of “973” project.

He has been working in the field of endocrine & metabolic diseases for years and mainly achieved in endocrine tumor and diabetes. He has published 500 papers in peer-reviewed journals, including Science,JAMA, Nat Cell Biol、JACC、Nat Med. He was winner of the National Science and Technical Progress Awards (2nd class) in 2008, 2010, 2012 and 2017 respectively (two rank first place and one rank second place). He was winner of Shulan Medicine Award (2017), Chinese Physician Award (2014), Wu Jieping Medicine Innovation Prize, Bai Qiuen like doctor, International Endocrinology Award from American Association of Clinical Endocrinologists, Lifetime Achievement Award from Israel Diabetes Association and Ministry of Health.

She is passionate about improving services for people with diabetes-related foot disease and is a member of the ADS Foot Network Working Group, a driving force for the NSW Agency for Clinical Innovation Standards for High Risk Foot Services and implementation across NSW and a member of the NSW Diabetes Taskforce. She has convened numerous practical education events for clinicians and is the CI for a multi-site RCT of debridement frequency in diabetes-related foot ulcers.

He leads several international clinical trials, and has been involved in developing Australian and global treatment guidelines. He has played a central role in the development of an affordable dialysis system, which was a Eureka Prize finalist in 2017.

Vlado is the President of the Association of Australian Medical Research Institute and is on the Board of the Australian Clinical Trials Alliance. He is Chair of the International Society of Nephrology Advancing Clinical Trials (ISN-ACT) group; and is a Fellow of the Royal Australasian College of Physicians, and the Australian Academy of Health and Medical Sciences. He serves on the Editorial Boards of a number of leading specialist and general journals, including the Journal of the American Society of Nephrology, Circulation, and the New England Journal of Medicine.

Prof Ritchie leads an internationally-recognised dynamic research program identifying new strategies to treat heart-failure, particularly secondary to diabetes and myocardial infarction. Her research achievements to date have enabled her to identify potential new treatment strategies, both pharmacological and gene delivery-based, for arresting the progression of heart failure in preclinical models of human disease. Of relevance for this forum, one of her breakthrough discoveries is that maladaptive glucose metabolism towards the sugar β-N-acetylglucosamine (increased in diabetic human heart) is a critical regulator of diabetic heart phenotype. Prof Ritchie is internationally-recognised for her contributions to cardiac pharmacology, with ~100 career publications. Her efforts have been recognised by the 2012 Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Achievement Award, the 2013 Diabetes Australia Millenium-Type 1 Diabetes Award, and election as a Fellow of the American Heart Association in 2013. Prof Ritchie makes exceptional contributions to Discipline, across executive positions in the International Society of Heart Research (Membership Secretary), Science & Technology Australia (representing Medical-Sciences) and ASCEPT, in addition to major contributions to grant peer review and to mentoring across all career levels in STEMM.

His clinical and research activities have focused on exploring novel agents and therapeutic strategies to improve glycemic control, particularly early insulin intervention with combination strategies in Type 2 Diabetes helping to develop the concept of fixed-ratio combination of Basal Insulin with a GLP-1 RA. Over the last 30 years, he has participated in hundreds of clinical trials and has had an active role in the development of new oral agents and insulin preparations acting often as a lead clinical investigator and scientific advisor. More recently, he has developed extensive experience conducting clinical trials testing the use of SGLT2 inhibitors as adjuvant therapy in T1DM.

Dr Rosenstock has been the author or co-author of 522 publications, including 285 peer-reviewed manuscripts and numerous abstracts. He has also contributed to 13 book chapters on various topics in the field of diabetes. Dr Rosenstock is a member of the National Board of Directors of the American Diabetes Association (ADA). He is currently Associate Editor of Diabetes Care, and also Editorial Board member of Practical Diabetology and Cardiovascular Diabetology as well as an active reviewer for several journals.  Dr Rosenstock has chaired or been a featured speaker at multiple lectures and presentations both nationally and internationally.

Tony has over 100 peer reviewed publications. He was sub-editor for Endocrinology of the Internal Medicine Journal 2015 to 2018. Tony has been on the Endocrinology expert group for Therapeutic Guidelines and on the expert advisory group for the NHMRC guidelines on Type 1 diabetes.

Tony currently sits on council of the Australian Diabetes Society. He has contributed to the Models of Care subgroup of the National Association for Diabetes Centres, and on the Integrated Care Subgroup for the Royal Australian College of Physicians.

Her translational research into hypothalamic control of appetite, energy expenditure, body weight and body composition spans studies with transgenic mice to randomized controlled weight loss trials in adults with overweight or obesity. Her current randomized controlled trials comparing long-term effects of fast versus slow weight loss – using intermittent versus continuous energy restriction – are funded by a Senior Research Fellowship and Project Grants from the National Health and Medical Research Council of Australia. She is the author of two books about adult weight management that are available internationally in three languages.

Carmel has co-authored international clinical guidelines for type 1 diabetes in Preschool Diabetes, Nutrition and most recently the new Paediatric Ramadan guidelines.  She is an invited member of an international collaboration charged with translating evidence on exercise management in diabetes into practice. Over the past 25 years Carmel has worked with many young children living with type 1 diabetes and would like to acknowledge them and their families.

Since 1985, Dr. Tan has been a resource person, organizer and initiator in numerous diabetes and educational related activities in Malaysia. These activities include as reviewer and taskforce member for Clinical Practice Guidelines, initiated the development of Diabetes Education Manual and Forum for Injectable Therapy Guideline, chaired the Melaka Diabetes Association branch, Diabetes Education Consultative Section of the Malaysian Diabetes Association and the Vice-president of the Malaysian Diabetes Educators Society. Her main contribution to diabetes education in Malaysia is initiating and organizing regular National Diabetes Education Conferences/ Seminars/Workshop to provide continuous diabetes education for local and South-East Asia diabetes educators and healthcare professionals with the aim to raise the standard of diabetes education in the country and globally.

Peter completed his PhD in the field of retinal vascular biology at Flinders University and his post-doctoral fellowship in regeneration of the central nervous system in multiple sclerosis, at the University of Cambridge, UK. Peter’s research is focused on novel imaging technologies to detect early markers of eye and central nervous system diseases, with a focus on Alzheimer’s disease.

Peter is a member of the medical and research committees of Macular Disease Foundation Australia, a Board member of the Ophthalmic Research Institute of Australia and is the Royal Australia and New Zealand College of Ophthalmologists (RANZCO) representative on the Vision 2020 Vision Initiative. He is a member of the Futures of Ophthalmology Taskforce of RANZCO and is Clinical Director of the KeepSight Program, a new national program for diabetic retinopathy screening.

Alongside his PhD studies, Chris helped to establish the Royal Melbourne Fracture Liaison Service to improve the detection and treatment of osteoporosis. He then undertook a postdoctoral fellowship with Professor Rajesh Thakker at the University of Oxford studying the molecular biology of neuroendocrine tumours. He is now employed as an Endocrinologist at the Royal Melbourne Hospital, where he is the Stream Leader for Pituitary and Neuroendocrine Tumours and Deputy Head of Bone and Mineral Medicine. He is also the Director of Endocrine Research and an Obstetric Endocrine physician at Western Health. His current research interests include: the molecular pathogenesis of pituitary adenomas, the clinical utility of peripheral quantitative CT in fracture prediction, and the use of continuous glucose monitoring to assess steroid-induced diabetes.

He leads the Intestinal Nutrient Sensing Group at the South Australian Health & Medical Research Institute (SAHMRI), with support from the NHMRC, ARC and Diabetes Australia. His group investigates the intestinal sweet taste system, which senses sugars and artificial sweeteners beyond the tongue, and can, in turn, regulate the release of hormones that control glucose uptake and disposal. He has shown changes in this system in human type 2 diabetes, critical illness and obesity, and its consequences for blood glucose control and nutrient delivery.

He collaborates with researchers and industry in this translational research to develop new therapies to treat type 2 diabetes and obesity.

Natasha has experience in assisting medical professionals with their taxation obligations and setting up and managing large multi-site practices.

This experience allows Natasha and the team at LDB to have a broad range of knowledge across the various accounting and taxation issues faced in multiple industries including the medical industry. This experience puts LDB in a position to provide excellent advice and client support and service for all client industries.